# AGENDA

**Friday, December 11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:00 a.m. | Registration — Third Floor Promenade  
Continental Breakfast — America’s Hall |

## Introductions

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 7:15 a.m. | Shalom Jacobovitz  
*Chief Executive Officer  
American College of Cardiology* |
|         | Kim A. Williams, MD, FACC  
*President  
American College of Cardiology* |
|         | William E. Lawson, MD, FACC  
*Governor, New York State Chapter  
American College of Cardiology* |

## Coronary Artery Disease — Challenges in 2015

### Session I: New Discoveries in Athero-thrombogenesis and Technologies

**Dr. Bhatt, Presiding**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 7:30 a.m. | Non-invasive Evaluation of Subclinical Atherosclerotic Disease Burden  
A Powerful Prognostic Tool Implicating Heart, Brain and Aging  
*Dr. Fuster* |
| 8:00 a.m. | Invasive Evaluation of High Risk or Vulnerable Plaque  
A Powerful Therapeutic Tool to Address Potential Pharmacological Agents  
*Dr. Narula* |
| 8:25 a.m. | The Role of the Various Monocyte Types in Athero-thrombotic Disease  
Protective vs. Detrimental Effects and Therapeutic Implications  
*Dr. Nahrendorf* |
| 8:50 a.m. | Panel Discussion  
*Drs. Fuster, Nahrendorf and Narula* |
| 9:20 a.m. | Coffee Break |

## Session II: Acute Coronary Syndromes (ACS)

**Dr. Bonow, Presiding**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 a.m.</td>
<td>ACS – Recent and Evolving Aspects</td>
</tr>
</tbody>
</table>
Definition and Diagnostics, Acquired and Genetic Factors, Ischemic and Reperfusion Injury
*Dr. Kovacic*

**10:05 a.m.**  
**ACS: Timing-related Strategies or a Most Critical Issue**?  
Timing to Reperfusion, Timing of Culprit vs. Multivessel Approach, Timing of DAPT  
*Dr. Granger*

**10:30 a.m.**  
**ACS: Antiplatelet, Anticoagulant Therapy and Combinations**  
The Challenge of a High Benefit/Bleeding Ratio  
*Dr. Bhatt*

**10:55 a.m.**  
**ACS: Non-antithrombotic Medical Options**  
Old Agents and New Lines on the Horizon  
*Dr. Boden*

**11:25 a.m.**  
**Panel Discussion**  
Drs. Bhatt, Boden, Granger and Kovacic

**12:00 p.m.**  
Lunch

---

**Session III: Chronic Coronary and Systemic Arterial Disease**  
*Dr. Boden, Presiding*

**1:00 p.m.**  
**Complex Stable CAD: Evolving Management Strategies**  
Anatomy (SYNTAX), Ischemia (FAME), Microcirculation (BARI) and the Polypill (FREEDOM)  
*Dr. Fuster*

**1:25 p.m.**  
**Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies**  
Presence or Absence of Ischemia and Viability Testing (STICH)  
*Dr. Bonow*

**1:45 p.m.**  
**Carotid Disease: How the 2014-2015 Data Will Influence Management**  
The Symptomatic vs. the Asymptomatic Patient Challenges  
*Dr. White*

**2:05 p.m.**  
**Peripheral Vascular Disease: Watch the Heart and the Brain**  
Evolving Role of Exercise, ACE-inhibitors, Interventional and Surgical Options  
*Dr. Creager*

**2:25 p.m.**  
**Panel Discussion**  
Drs. Bonow, Creager, Fuster and White

**2:55 p.m.**  
Coffee Break

As of 6/26/15
Session IV: Trends and Challenges of Prevention

Dr. Williams, Presiding

3:15 p.m. Recent ACC/AHA Guidelines on Lipids, Already Getting Older
From Ezetimibe/Simvastatin (IMPROVE IT) to PCSK9 Inhibitors
Dr. Sabatine

3:35 p.m. New U.S. (and ESH/ESC) Statements on Hypertension; Healthy Controversy?
From Population Salt Reduction to Personalized Treatment Targets?
Dr. Rosendorff

3:55 p.m. The Link Between Obesity and Diabetes
The Rapid Evolution and Positive Results of Bariatric Surgery
Dr. McGuire

4:15 p.m. Aspirin Therapy in Primary Cardiovascular Disease Prevention
Only for Those at High Cardiovascular Risk, the Dose Under Trials
Dr. De Caterina

4:35 p.m. Targeting Programs of Promoting Cardiovascular Health Are
Finally Providing Data of Benefit
Targeting Children (Ages 3 to 5), the Family and the Community
Dr. Fuster

4:55 p.m. Panel Discussion
Drs. De Caterina, Fuster, McGuire, Rosendorff and Sabatine

5:30 p.m. Adjournment

Saturday, December 12

6:15 a.m. Continental Breakfast

Cardio-pulmonary and Electrical Failure 2015
Session V: Systolic Heart Failure and Basis for Management

Dr. O’Connor, Presiding

7:00 a.m. MOGE(S) or Clinical-genetic Classification of Cardiomyopathy and a Follow-up Critique
The Term “Idiopathic” in the Process of Eradication
Dr. Narula

7:20 a.m. The 2015 Diagnostic and Prognostic Imaging (MR, CT) of the Various
Cardiomyopathies:
Myocarditis, Dilated, Infiltrative (Amyloid, Sarcoid), Hypertrophic, Noncompaction
Dr. H. Halperin

7:40 a.m. Systolic Dysfunction: Clinical/Hemodynamic Guide for Management
New Medical and Interventional Therapeutic Challenges
Dr. Mancini

8:00 a.m. Diastolic Dysfunction: Clinical/Hemodynamic/Comorbid Features
Should Prognosis/Management Be Focused on the Comorbidities?
Dr. O’Connor

8:20 a.m. Destination LVADs: Advances 2014-2015
A Rapidly Evolving Alternative to Heart Transplantation
Dr. Pinney

8:40 a.m. Percutaneous Mechanical Circulatory Support Devices
Hemodynamic Effects, Clinical Outcomes, Risks and Knowledge Gaps
Dr. Rihal

9:00 a.m. 2015 State-of-the-Art Management of Pulmonary Hypertension
Based on an Understanding of the Various Etiologies
Dr. McLaughlin

9:20 a.m. Panel Discussion
Drs. Halperin, Mancini, McLaughlin, Narula, Pinney, O’Connor and Rihal

10:00 a.m. Coffee Break

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus
Dr. Reddy, Presiding

10:20 a.m. Heart Failure Device Therapy: ICD and CRT
Systolic Dysfunction, Diastolic Dysfunction, Mitral Regurgitation
Dr. Ellenbogen

10:40 a.m. Ventricular Tachycardia: Catheter Ablation
How? When?
Dr. Wilber

11:00 a.m. Atrial Fibrillation 2015: The 14 Clinical Challenges
Quality of Life and Preventing Stroke
Dr. Fuster

11:20 a.m. Atrial Fibrillation: Catheter Ablation with New Technologies
Improving Quality of Life and Outcomes in Various Disease States
Dr. Wilber

11:40 a.m. A New Job for the EP Community: Plumbing Electrical Dysfunction and
Thromboembolism
Wireless “Boxes” and Protecting “Umbrellas”
Dr. Reddy
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12:00 p.m.| Panel Discussion<br>

*Drs. Ellenbogen, Fuster, Reddy and Wilber*

| 12:30 p.m.| Lunch                                                            |

---

Valvular Heart Disease and Aorta — Challenges in 2015

Session VII: Management of Aortic Valve Disease, IHSS and Aorta

*Dr. Carabello, Presiding*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1:30 p.m. | Aortic Valvular Stenosis, Asymptomatic, Severe, Age 60 Years<br>

*From Medical Therapy, to Surgical AVR, to Transcatheter AVR/Valvuloplasty*

  The Clinician’s View – Dr. Bonow
  The Surgeon’s View – Dr. Bavaria
  The Interventionalist’s View – Dr. Sharma

| 1:50 p.m. | Aortic Valvular Stenosis, Symptomatic Severe, Low Flow/ Low Gradient, Age 60 Years<br>

*From Medical Therapy to Surgical AVR to Transcatheter AVR/Valvuloplasty*

  The Clinician’s View – Dr. Bonow
  The Surgeon’s View – Dr. Bavaria
  The Interventionalist’s View – Dr. Sharma

| 2:10 p.m. | 2015 Prevalence, Genetics and Approach to the Management of HCM<br>

*Evidence and Uncertainties*

*Dr. Maron*

| 2:35 p.m. | Aortic Valvular Incompetence, Asymptomatic, EF 45%, Age 60 Years<br>

*From Medical Therapy to Surgical AVR to Transcatheter AVR (?)*<br>

  The Clinician’s View – Dr. Bonow
  The Surgeon’s View – Dr. Bavaria
  The Interventionalist’s View – Dr. Sharma

| 2:55 p.m. | Aortic Valvular Incompetence, Symptomatic, Infective Endocarditis, Age 25 Years<br>

*From Medical Therapy to Surgical AVR to Transcatheter AVR (?)*<br>

  The Clinician’s View – Dr. Bonow
  The Surgeon’s View – Dr. Bavaria
  The Interventionalist’s View – Dr. Sharma

| 3:15 p.m. | The Dilated Thoracic and Abdominal Aorta and Complicating Dissection<br>

*Evolving Understanding of the Basic Biology and Management*

*Dr. Fuster*

| 3:40 p.m. | Panel Discussion                                                    |
Drs. Bavaria, Bonow, Fuster, Maron and Sharma

4:00 p.m.  Coffee Break

Session VIII: Management of Mitral Regurgitation
Dr. Bavaria, Presiding

4:20 p.m.  Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years
From Medical Therapy to Surgical Repair to Transcatheter Intervention

The Clinician’s View – Dr. Carabello
The Surgeon’s View – Dr. Anyanwu
The Interventionalist’s View – Dr. Feldman

4:40 p.m.  Primary Mitral Valve Regurgitation without/with Heart Failure, Age 60 Years

The Clinician’s View – Dr. Carabello
The Surgeon’s View – Dr. Anyanwu
The Interventionalist’s View – Dr. Feldman

5:00 p.m.  Panel Discussion
Drs. Anyanwu, Carabello and Feldman

5:30 p.m.  Adjournment

Sunday, December 13

6:30 a.m.  Continental Breakfast

YEAR IN REVIEW: 10 HIGHLIGHTS OF PROGRESS IN 2015
Dr. Fuster, Presiding
Session IX: Novelties on Genetics, Cell Regeneration and Molecular Signaling

7:30 a.m.  HENRY RUSSEK LECTURE 2015
The microRNAs: Evolving Critical Players in the Field of Medicine
Genetic and Molecular Bases for a Better Understanding of Cardiovascular Physiology
and Pathology
Dr. Mayr

7:55 a.m.  Induced Pluripotent Stem Cells: Predicting a Powerful Future
Dr. Wu

8:15 a.m.  Follow-up of the CUPID Gene Therapy Studies
A Roadmap for Enhancement of Myocardial Metabolism and Viability
Dr. Hajjar

As of 6/26/15
Section X: Novelties on Diagnostic Strategies

8:35 a.m. Coronary Artery Manifestations of Fibromuscular Dysplasia
An Infrequent Condition, but Easily Missed

Dr. Olin

8:55 a.m. Sleep Apnea: Types, Mechanisms and Clinical Cardiovascular Consequences
A Frequent Condition, but Easily Missed

Dr. Javaheri

9:15 a.m. LV Non-compaction: A Distinct Genetical Cardiomyopathy?
Perhaps Less Frequent and Less Threatening than Previously Advertised

Dr. Arbustini

9:35 a.m. Cardio-oncology Evolving into Prime Time Status
Prevention of Anthracycline-induced Cardiotoxicity

Dr. Yeh

9:55 a.m. Thromboembolism During NSR in Patients with a History of Atrial Fibrillation
Is Left Atrial Appendix Dysfunction Sufficient to Generate the Cloth?

Dr. J. Halperin

10:15 a.m. Coffee Break

Section XI: Novelties on Therapeutic Strategies

10:25 a.m. The Evolving Science of Stents
Current Status of Bioresorbable Scaffolds: Moving Forward or Backwards?

Dr. Hamm

10:45 a.m. PAUL DUDLEY WHITE LECTURE 2015
The Historical Path to an Angiotensin Receptor Antagonist-neprilysin Inhibitor
A New and Exciting Pharmacological Approach to the Management of CHF

Dr. Braunwald

11:15 a.m. Closing Remarks

Dr. Fuster

11:30 a.m. Course Adjournment

As of 6/26/15